Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 1

Interventions

pembrolizumab 135Carboplatin 111Paclitaxel 68Cisplatin 65Gemcitabine 62Pemetrexed 59Bevacizumab 50Docetaxel 47Fluorouracil 42Oxaliplatin 40Leucovorin 35Dexamethasone 35130-nm albumin-bound paclitaxel 34durvalumab 32atezolizumab 32Cetuximab 32Nivolumab 31Capecitabine 28Rituximab 27Cyclophosphamide 27Prednisone 26Fulvestrant 25enzalutamide 23Lenalidomide 23Letrozole 22venetoclax 21Irinotecan 21Doxorubicin 19ribociclib 16pomalidomide 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Hydroxyurea × 30 days × Clear all
NCT05020652 2026-06-02

A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Completed
107 enrolled
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡